201 related articles for article (PubMed ID: 33368420)
1. Regulatory environment for novel therapeutic development in mitochondrial diseases.
Hirano M; Berardo A; Barca E; Emmanuele V; Quinzii C; Simpson CV; Engelstad K; Rosales XQ; Thompson JLP
J Inherit Metab Dis; 2021 Mar; 44(2):292-300. PubMed ID: 33368420
[TBL] [Abstract][Full Text] [Related]
2. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
3. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
4. Drug development for rare mitochondrial disorders.
Hurko O
Neurotherapeutics; 2013 Apr; 10(2):286-306. PubMed ID: 23430661
[TBL] [Abstract][Full Text] [Related]
5. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
Mechler K; Mountford WK; Hoffmann GF; Ries M
Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
[TBL] [Abstract][Full Text] [Related]
6. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
Tambuyzer E
Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
[TBL] [Abstract][Full Text] [Related]
7. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
Burke KA; Freeman SN; Imoisili MA; Coté TR
Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
[TBL] [Abstract][Full Text] [Related]
8. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
9. Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis.
Döring JH; Lampert A; Hoffmann GF; Ries M
PLoS One; 2016; 11(8):e0161660. PubMed ID: 27557111
[TBL] [Abstract][Full Text] [Related]
10. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
Le TT
Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
[TBL] [Abstract][Full Text] [Related]
11. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
12. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act.
Fermaglich LJ; Miller KL
Orphanet J Rare Dis; 2023 Jun; 18(1):163. PubMed ID: 37353796
[TBL] [Abstract][Full Text] [Related]
14. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
[TBL] [Abstract][Full Text] [Related]
15. History of Orphan Drug Regulation-United States and Beyond.
Haffner ME
Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
[TBL] [Abstract][Full Text] [Related]
16. The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success.
Saltonstall P; Ross H; Kim PT
Milbank Q; 2024 Mar; 102(1):83-96. PubMed ID: 38087888
[TBL] [Abstract][Full Text] [Related]
17. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
18. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
19. Exploring the Potential Challenges for Developing Generic Orphan Drugs for Rare Diseases: A Survey of US and European Markets.
Murthannagari VR; Gonna Nandhi Krishnan G; Manu KV; Jayachandraiah CT; Mandadhi Rajendra PK; Ahmed SS
Value Health Reg Issues; 2023 May; 35():87-94. PubMed ID: 36921379
[TBL] [Abstract][Full Text] [Related]
20. The Orphan Drug Act Revisited.
Thomas S; Caplan A
JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
[No Abstract] [Full Text] [Related]
[Next] [New Search]
